PW 2101

Drug Profile

PW 2101

Latest Information Update: 04 Jul 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Penwest Pharmaceuticals
  • Class Antihypertensives
  • Mechanism of Action Beta-adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hypertension

Most Recent Events

  • 04 Jul 2005 Discontinued - Preregistration for Hypertension in USA (PO)
  • 04 Jul 2005 Penwest has received a non-approvable letter from the US FDA for PW 2101 in hypertension
  • 27 Apr 2005 PW 2101 has been licensed to Prism Pharmaceuticals in the US and Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top